Zafrens has built ultra-high-throughput single-cell drug screening, compressing what is normally a sequence of plate-based experiments into assays that measure responses cell by cell at very large scale. Conventional screening reads the average behaviour of a well, which hides exactly the signal that often matters: a subpopulation that responds strongly, resists treatment, or shows the toxicity that only appears in a minority of cells. Averaging is cheap, but it discards the heterogeneity that determines whether a candidate works in a patient.

Reading single cells at throughput changes what is affordable to ask early in discovery, letting teams triage candidates on richer evidence before committing to expensive downstream work. Backed since 2023 and funded through a 23 million dollar Series A, Zafrens sits in the same tools layer as other deep-domain holdings: the customer is the researcher, the moat is instrumentation and assay chemistry, and adoption compounds as published results accumulate. Because the platform sells to every therapeutic area rather than one, its market expands with the industry rather than with a single program.